Mode
Text Size
Log in / Sign up
Phase 4 Completed N=11 Prevention

Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)

Source: ClinicalTrials.gov NCT01134952 ↗
Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Jan 2015
Primary outcomePrimary: Delta Hepatitis C Viral Load — 15 percent change

Summary

Different immunosuppressive drugs used in transplantation may reduce the body's defences against infection differently. It is known that patients with Hepatitis C virus, known as HCV, who switched from azathioprine to mycophenolate mofetil experienced an increase in viral load. Despite this, mycophenolate mofetil is used because it prevents rejection more reliably than azathioprine. Sirolimus is an another immunosuppressive agent that reliably prevents rejection and may have antiviral activity. This study is designed to see if the viral load of HCV and other viruses is reduced by switching from mycophenolate to sirolimus.

Outcome Measures

OutcomeResultp-value
PRIMARY
Delta Hepatitis C Viral Load
15
SECONDARY
Final Hepatitis C Viral Load
-47
SECONDARY
Sirolimus Trough Level
7.2
SECONDARY
Delta Tacrolimus Trough Level
23
SECONDARY
Delta Bilirubin
-6.0
SECONDARY
Delta Alkaline Phosphatase
13.8
SECONDARY
Delta Alanine Aminotransferase
9
SECONDARY
Delta Hemoglobin
-2.7
SECONDARY
Delta Platelet Count
-8.5
SECONDARY
Delta Cholesterol Fasting Level
1.2
SECONDARY
Delta Triglyceride Fasting Level
23

Eligibility Criteria

Inclusion Criteria

  • Recurrent HCV after liver transplantation
  • Taking mycophenolate mofetil
  • Stable liver function

Exclusion Criteria

  • Pregnant females or couples unwilling to use contraception
  • Intolerance or allergy to sirolimus
  • Patients taking anti-HCV therapy
  • Patients taking medications known to alter the levels of sirolimus
  • History of thromboembolic disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01134952). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search